William Blair Forecasts Exagen's Q1 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN - Free Report) - Investment analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Exagen in a report issued on Monday, May 5th. William Blair analyst A. Brackmann forecasts that the company will post earnings per share of ($0.08) for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen's Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.04) EPS.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). The business had revenue of $15.50 million for the quarter, compared to analysts' expectations of $14.55 million. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. During the same period last year, the business earned ($0.19) EPS.

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $8.00 price objective on shares of Exagen in a research report on Monday, January 13th.

Exagen Price Performance

Shares of XGN opened at $6.42 on Wednesday. The company has a 50 day moving average of $4.36 and a two-hundred day moving average of $4.04. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. Exagen has a twelve month low of $1.35 and a twelve month high of $7.00. The company has a market cap of $115.57 million, a price-to-earnings ratio of -6.83 and a beta of 1.50.

Hedge Funds Weigh In On Exagen

Several hedge funds and other institutional investors have recently modified their holdings of XGN. Corient Private Wealth LLC acquired a new stake in Exagen during the 4th quarter worth about $45,000. Virtu Financial LLC purchased a new position in shares of Exagen in the fourth quarter worth about $46,000. Marshall Wace LLP acquired a new stake in shares of Exagen during the fourth quarter worth about $66,000. Northern Trust Corp boosted its position in Exagen by 16.7% in the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock valued at $75,000 after buying an additional 2,630 shares during the last quarter. Finally, Huntleigh Advisors Inc. boosted its position in Exagen by 16.8% in the first quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company's stock valued at $298,000 after buying an additional 11,939 shares during the last quarter. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.